Sources Say Amgen Plans To Sell Biotech Japanese Unit (Japan)
This article was originally published in PharmAsia News
Executive Summary
The world's largest biotechnology company, Amgen plans cost reductions, beginning by closing its Japan unit, according to sources. U.S.-based Amgen is suffering a decline in sales and is asking $403 million for its Tokyo operation, beginning the talks with Japanese drugmakers. A spokeswoman called the reports "speculation." The Japan unit develops biotech treatments for asthma, cancer and rheumatoid arthritis in Japan. (Click here for more
You may also be interested in...
Takeda Makes $1 Billion Move For Amgen Development Rights
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.